Exhibit 3 Time and Cost to Obtain Phase II Data for CRP-1 (Bum Treatment) Using a New Pilot
Facility for Clinical-grade Production of CRP-1. Midrange estimate. ($000)
Pilot Facility
1991
1992
1993
Total Thru
12/93
Construction and Equipment Costs
3,100
0
0
3,100
Variable Production Expenses and Overhead
0
800
1,204
2,004
Pre-Clinical Development
250
0
0
250
Clinical Trials (Phase I/II)
0
1,040
1,000
2,040
Total
3,350
1,840
2,204
7,394
Exhibit 4 Time and Cost to Obtain Phase II Clinical Trial Data for CRP-1 (Burn Treatment) Using
Contract Production for Clinical-grade CRP-1.
1991
1992
1993
Total Thru
12/93
Contract Production and Related Expense
0
955
1,550
2,505
Pre-Clinical Development
250
0
0
250
Clinical Trials (Phase I/II)
0
1,040
1,000
2,040
Total
250
1,995
2,550
4,795
Exhibit 5 Estimated Gross Sales of CRP-1
Year
1998
1999
2000
2001
2002
(as topical burn wound treatment)
Sales ($thousands)
53,700
99,500
125,000
130,000
150,000
After the year 2000, sales of CRP-1 as a bum wound
treatment were expected to grow at approximately 5% per
year, assuming no introduction of a substitute product.